We’re only three months into 2017, but it’s already been a great year for marijuana science.
Numerous marijuana studies have been released so far this year; these studies are wide-ranging in the medical ailments cannabis is found to benefit, and in the positive effects brought forth by a liberalization of the laws surrounding it.. We’ve narrowed these studies down to the 10 most important, with a few honorable mentions.
2014 has been an incredible year for the cannabis reform movement, with two more states, several cities and the District of Columbia voting in favor of legalization. In addition, it’s been an excellent year for cannabis science, with numerous studies being released that demonstrate its medical potential and diversity, and the benefits of its legalization. Below we breakdown what we believe to be the top 10 cannabis studies of 2014.
A study published by the Journal of the American Medical Association Internal Medicine in January found that states that have legalized medical cannabis have seen a drastic reduction in opioid overdose mortality rates. According to the study; “States with medical cannabis laws had a 24.8% lower mean annual opioid overdose mortality rate compared with states without medical cannabis laws.” Researchers note that the reduction was almost immediate, as every state that legalized medical cannabis saw a dramatic decrease in opioid overdose deaths within the first year (averaging about 20% less). The decline continued each year after. By the 5th year, states had experienced a decrease in opioid deaths ranging up to 50.9%.
In his 2014 budget proposal Colorado Governor John Hickenlooper is calling for over $7 million in funding for “legitimate” studies examining the medical benefits of cannabis. Under the proposal, grants sized between $500,000 and $1 million would be distributed to universities, research hospitals, foundations and so forth, in order to study cannabis’ effect on conditions such as epilepsy, and post-traumatic stress disorder..
In recent years numerous studies have found that cannabis can protect the skeleton against age-related bone loss, including diseases such as osteoporosis.
A 2009 study published by the journal Annals of Medicine found that “the main physiologic involvement of CB2 [cannabinoid receptor type 2] is associated with maintaining bone remodeling at balance, thus protecting the skeleton against age-related bone loss.”
A 2010 study published by the National Institute of Health concludes: “This review summarises in vitro and in vivo findings relating to the influence of cannabinoid ligands on bone metabolism and argues in favour of the exploitation of cannabinoid receptors as targets for both anabolic and anti-resorptive therapy for treatment of complex multifaceted bone diseases such as osteoporosis.”